Effectiveness of remdesivir with corticosteroids for COVID‐19 patients in intensive care unit : A hospital‐based observational study
Abstract The effectiveness of remdesivir on survival in coronavirus disease 2019 (COVID‐19), especially in cases treated in the intensive care unit (ICU), is controversial. We investigated the effectiveness of remdesivir with corticosteroids on the survival of COVID‐19 patients in a real ICU clinical practice. For laboratory‐confirmed COVID‐19 patients admitted to the ICU of a tertiary hospital in Tokyo (April 2020–November 2021) and who received corticosteroids, the effectiveness of remdesivir for survival, stratified by interval length (within 9 or 10+ days), was retrospectively analyzed using Cox regression model. A total of 168 patients were included: 35 with no remdesivir use (control), 96 with remdesivir use within 9 days, and 37 with remdesivir use with an interval of 10+ days. In‐hospital mortality was 45.7%, 10.4%, and 16.2%, respectively. After adjusting for possible covariates including comorbidities, laboratory data, oxygen demand, or level of pneumonia, remdesivir use within 9 days from symptom onset reduced mortality risk (hazard ratio [HR]: 0.10; 95% confidence interval (CI): 0.025–0.428) compared to the control group. However, remdesivir use with an interval of 10+ days showed no significant association with mortality (HR: 0.42; 95% CI: 0.117–1.524). Among COVID‐19 patients who received corticosteroids in ICU, remdesivir use within 9 days from symptom onset was associated with reduced in‐hospital mortality risk..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:95 |
|---|---|
| Enthalten in: |
Journal of Medical Virology - 95(2023), 1 |
| Beteiligte Personen: |
Hanafusa, Mariko [VerfasserIn] |
|---|
| Anmerkungen: |
© 2023 Wiley Periodicals LLC. |
|---|
| Umfang: |
10 |
|---|
| doi: |
10.1002/jmv.28168 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY009007768 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY009007768 | ||
| 003 | DE-627 | ||
| 005 | 20231111175708.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230217s2023 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/jmv.28168 |2 doi | |
| 028 | 5 | 2 | |a 2023-11-11_JMV_2023_95_1.zip.xml |
| 035 | |a (DE-627)WLY009007768 | ||
| 035 | |a (WILEY)JMV28168 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 100 | 1 | |a Hanafusa, Mariko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of remdesivir with corticosteroids for COVID‐19 patients in intensive care unit |b A hospital‐based observational study |
| 264 | 1 | |c 2023 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 Wiley Periodicals LLC. | ||
| 520 | |a Abstract The effectiveness of remdesivir on survival in coronavirus disease 2019 (COVID‐19), especially in cases treated in the intensive care unit (ICU), is controversial. We investigated the effectiveness of remdesivir with corticosteroids on the survival of COVID‐19 patients in a real ICU clinical practice. For laboratory‐confirmed COVID‐19 patients admitted to the ICU of a tertiary hospital in Tokyo (April 2020–November 2021) and who received corticosteroids, the effectiveness of remdesivir for survival, stratified by interval length (within 9 or 10+ days), was retrospectively analyzed using Cox regression model. A total of 168 patients were included: 35 with no remdesivir use (control), 96 with remdesivir use within 9 days, and 37 with remdesivir use with an interval of 10+ days. In‐hospital mortality was 45.7%, 10.4%, and 16.2%, respectively. After adjusting for possible covariates including comorbidities, laboratory data, oxygen demand, or level of pneumonia, remdesivir use within 9 days from symptom onset reduced mortality risk (hazard ratio [HR]: 0.10; 95% confidence interval (CI): 0.025–0.428) compared to the control group. However, remdesivir use with an interval of 10+ days showed no significant association with mortality (HR: 0.42; 95% CI: 0.117–1.524). Among COVID‐19 patients who received corticosteroids in ICU, remdesivir use within 9 days from symptom onset was associated with reduced in‐hospital mortality risk. | ||
| 700 | 1 | |a Nawa, Nobutoshi |4 aut | |
| 700 | 1 | |a Goto, Yuki |4 aut | |
| 700 | 1 | |a Kawahara, Tomoki |4 aut | |
| 700 | 1 | |a Miyamae, Shigeru |4 aut | |
| 700 | 1 | |a Ueki, Yutaka |4 aut | |
| 700 | 1 | |a Nosaka, Nobuyuki |4 aut | |
| 700 | 1 | |a Wakabayashi, Kenji |4 aut | |
| 700 | 1 | |a Tohda, Shuji |4 aut | |
| 700 | 1 | |a Tateishi, Ukihide |4 aut | |
| 700 | 1 | |a Fujiwara, Takeo |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Medical Virology |g 95(2023), 1 |w (DE-627)WLY008980918 |x 10969071 |7 nnns |
| 773 | 1 | 8 | |g volume:95 |g year:2023 |g number:1 |g extent:10 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 95 |j 2023 |e 1 |g 10 | ||